"Sildenafil Citrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.
| Descriptor ID |
D000068677
|
| MeSH Number(s) |
D02.065.884.675 D02.886.590.700.675 D03.383.606.854 D03.633.100.759.824
|
| Concept/Terms |
Sildenafil Citrate- Sildenafil Citrate
- Citrate, Sildenafil
- 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
UK 92480-10- UK 92480-10
- UK 92480 10
- UK 9248010
- UK-92,480-10
- UK 92,480 10
|
Below are MeSH descriptors whose meaning is more general than "Sildenafil Citrate".
Below are MeSH descriptors whose meaning is more specific than "Sildenafil Citrate".
This graph shows the total number of publications written about "Sildenafil Citrate" by people in this website by year, and whether "Sildenafil Citrate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 6 | 6 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 5 | 5 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sildenafil Citrate" by people in Profiles.
-
Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis. Cardiol Young. 2023 Nov; 33(11):2297-2311.
-
Risk Stratification by Percent Liver Herniation in Congenital Diaphragmatic Hernia. J Surg Res. 2023 02; 282:168-173.
-
Continuous and intermittent administration of intravenous sildenafil in critically ill infants with pulmonary hypertension. Pediatr Pulmonol. 2021 09; 56(9):2973-2978.
-
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children. Pediatr Pulmonol. 2021 03; 56(3):593-613.
-
Syncope in a Child with Pulmonary Hypertension and Positive Gene Tests for Hereditary Hemorrhagic Telangiectasia and Long QT Syndrome. Cardiovasc Hematol Agents Med Chem. 2020; 18(1):70-76.
-
Prenatal intervention for the management of congenital diaphragmatic hernia. Pediatr Surg Int. 2018 Jun; 34(6):579-587.
-
VISION LOSS IN A PATIENT WITH PRIMARY PULMONARY HYPERTENSION AND LONG-TERM USE OF SILDENAFIL. Retin Cases Brief Rep. 2017 Fall; 11(4):325-328.
-
A Case Report of Fatal Desmethyl Carbodenafil Toxicity. J Anal Toxicol. 2017 Apr 01; 41(3):250-255.
-
AMPK and Endothelial Nitric Oxide Synthase Signaling Regulates K-Ras Plasma Membrane Interactions via Cyclic GMP-Dependent Protein Kinase 2. Mol Cell Biol. 2016 12 15; 36(24):3086-3099.
-
Evaluating the safety of intermittent intravenous sildenafil in infants with pulmonary hypertension. Pediatr Pulmonol. 2017 02; 52(2):232-237.